Human papillomavirus vaccine acceptability among a national sample of adult women in the USA
Nathan W. Stupiansky A D , Susan L. Rosenthal B , Sarah E. Wiehe C and Gregory D. Zimet AA Section of Adolescent Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
B Department of Pediatrics, Columbia University Medical Center, New York, NY 10032, USA.
C Children’s Health Services Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
D Corresponding author. Email: nstupian@indiana.edu
Sexual Health 7(3) 304-309 https://doi.org/10.1071/SH09127
Submitted: 27 November 2009 Accepted: 16 April 2010 Published: 19 August 2010
Abstract
Background: In the USA, the human papillomavirus (HPV) vaccine is currently licensed for 9–26-year-old females, but licensure for women over 26 years is being considered. The aim of the current study was to investigate the association of sociodemographic and health-related factors to HPV vaccine acceptability among adult women. Methods: The current study utilised a nationally representative sample of women (n = 1323) aged 27–55 living in the USA, with an oversampling of black and Latina women. A multiple item measure of HPV vaccine acceptability across varying cost and location-of-availability (clinic only v. any local pharmacy) conditions was the main outcome measure. General linear modelling was used to analyse the association of vaccine cost, location availability, and sociodemographic and health-related variables with vaccine acceptability. Results: Vaccine cost had the strongest association with acceptability [F (2, 1249) = 832.1; P < 0.0001]; however, factors such as religiosity, political views, a history of various negative sexual health outcomes and previous flu shot receipt were also associated with acceptability. Location availability had a statistically significant but modest effect, with a slight preference shown for health clinic availability. Conclusions: Adult women had generally high levels of HPV vaccine acceptability, but were greatly influenced by cost of the vaccine. Women who had experienced negative sexual health outcomes due to HPV-specific infection rated the vaccine as more acceptable, perhaps due to distress associated with those outcomes.
Additional keywords: acceptability, HPV, vaccination, women.
Acknowledgements
This study was funded by an investigator-initiated grant from Merck and Co.
[1] Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297 813–9.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
[2] Weinstock H, Berman S, Cates W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004; 36 6–10.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[3] Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88 63–73.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
[4] Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008; 113 3036–46.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[5] Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6 271–8.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[6] Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369 2161–70.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
[7] Hopenhayn C, Christian A, Christian W, Schoenberg N. Human papillomavirus vaccine: knowledge and attitudes in two Appalachian Kentucky counties. Cancer Causes Control 2007; 18 627–34.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[8] Black LL, Zimet GD, Short MB, Sturm L, Rosenthal SL. Literature review of human papillomavirus vaccine acceptability among women over 26 years. Vaccine 2009; 27 1668–73.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[9] Ferris DG, Waller JL, Owen A, Smith J. HPV vaccine acceptance among mid-adult women. J Am Board Fam Med 2008; 21 31–7.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[10] Sauvageau C, Duval B, Gilca V, Lavoie F, Ouakki M. Human papilloma virus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health 2007; 7 304.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[11] Jain N, Euler GL, Shefer A, Lu P, Yankey D, Markowitz L. Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey–Adult 2007. Prev Med 2009; 48 426–31.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[12] Schwarz TFS, Marek SA, Wysocki J, Galaj A, Perona P, Poncelet S, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15–55 years. Vaccine 2009; 27 581–7.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
[13] Muñoz N, Ricardo M, Punee P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet 2009; 373 1949–57.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[14] Caskey R, Lindau ST, Alexander GC. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health 2009; 45 453–62.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[15] Reece M, Sanders SA, Dodge B, Ghassemi A, Fortenberry JD. Prevalence and characteristics of vibrator use by men in the United States. J Sex Med 2009; 6 1867–74.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[16] Herbenick DRM, Sanders S, Dodge B, Ghassemi A, Fortenberry JD. Prevalence and characteristics of vibrator use by women in the United States: results from a nationally representative study. J Sex Med 2009; 6 1857–66.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[17] Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health 2007; 40 108–15.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[18] Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007; 45 107–14.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[19] Cates JR, Brewer NT, Fazekas KI, Mitchell CE, Smith JS. Racial differences in HPV knowledge, HPV vaccine acceptability, and related beliefs among rural, Southern women. J Rural Health 2009; 25 93–7.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[20] Scarinci IC, Garces-Palacio IC, Partridge EE. An examination of acceptability of HPV vaccination among African American women and Latina Immigrants. J Womens Health 2007; 16 1224–33.
| Crossref | GoogleScholarGoogle Scholar |
[21] Forster AS, Marlow LAV, Wardle J, Stephenson J, Waller J. Understanding adolescents’ intentions to have the HPV vaccine. Vaccine 2010; 28 1673–6.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[22] Skinner SR, Garland SM, Stanley MA, Pitts M, Quinn MA. Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26? Med J Aust 2008; 188 238–42.
| PubMed |
